Multiple myeloma

Indexed in Crossref

150 abstracts matching multiple myeloma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 11:06 UTC. This is a keyword search, not the complete abstract book.

• E19542
  Comparative outcomes of prophylactic anticoagulation in patients with multiple myeloma receiving immunomodulatory therapy.

  Ana Chachua, Alankrita Taneja
• E19502
  Comparison of talquetamab vs teclistamab in relapsed refractory multiple myeloma.

  Stephanie Niforatos, Devashish Desai, Bhaskara Reddy Madhira
• E19528
  Renal function eligibility in multiple myeloma CAR T and bispecific antibody clinical trials.

  Asma Qasim, M. Bakri Hammami
• E23437
  Real-world treatment patterns and clinical characteristics of patients with t(11;14)-positive multiple myeloma.

  Stacey Long, Colby Tubbs
• E19550
  SARS-CoV-2 infection, vaccination, and MGUS progression with COVID-19 outcomes in multiple myeloma: A systematic review.

  Rithika Manjunatha Reddy
• E19575
  Anti-CD38 treatment patterns in multiple myeloma patients with Medicare/Medicaid versus private insurance.

  Jessica Addis, Atish Gandhi, Khadega Abuelgasim Ahmed
• E19535
  Trends in U.S. pneumonia-related admissions among patients with multiple myeloma (2006–2022).

  Jackson R. Brunner, Kristian Seiler, Matthew J. Pianko
• E19529
  Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.

  Shreya Shambhavi, Harmanjeet Singh, Astha Grover, Tiffany Pompa
• E19555
  Trial-level association between age-enriched populations and treatment effect in frontline randomized multiple myeloma studies.

  Calvin Yee Fen Lee, Ehsan Malek
• E19545
  Empowering patients with multiple myeloma through the INSIST! program: Outcomes of biomarker testing education.

  Aicha M. Diallo, Tracy T. Rode, Joelys Gonzalez Bisono
• E22622
  Secondary multiple myeloma and antecedent cancer lineage.

  Kirti Arora, Kashish Magnani, Stuti Shah, Rishi Chowdhary et al.
• 7555
  Extrachromosomal DNA as a shaper of aggressive transcriptional states in multiple myeloma.

  Hyunsoo Cho, Hi Eun Jung, Chang Gon Kim, Hoon Kim
• E19573
  Early vs delayed bone-modifying agent initiation and zoledronic acid vs denosumab in newly diagnosed multiple myeloma.

  Farzeen Fatma Syed, Saad Javaid, Jennifer Collins, Amir Kamran
• 7575
  Plasma exchange in myeloma-associated acute kidney injury: A multicenter propensity-matched cohort study.

  Jarred Madison Boone, Joseph OBrien, Monica Nair, Timothy O'Brien
• E19561
  Real-world comparison of Dara-VRD, VRD, and Dara-RD in transplant-ineligible older adults with newly diagnosed multiple myeloma.

  Jayasree Krishnan, Anuja Vidyadhar Abhyankar
• 7558
  A machine learning (ML)–based six-gene signature for risk stratification and therapeutic target identification in multiple myeloma.

  Sriram Subramanian, Salman Aslam, Shahzad Raza
• E19534
  Real-world patterns of aspirin and anticoagulant prophylaxis at IMiD-associated VTE onset in multiple myeloma: A phase-specific analysis.

  Jeet Patel, Carley Pickett, Jeries Kort
• E19572
  Real-world comparison of remission status in newly diagnosed multiple myeloma treated with daratumumab-based versus bortezomib-based first-line therapy.

  Chander Perkash Khatri, Madho Mal, Jennifer Calafato
• 7556
  Enabling blood-based mass spectrometry MRD detection in multiple myeloma without archived serum samples.

  Daniel Jesus Groso, Katie Thoren, Carl Ola Landgren, David Glen Coffey
• E19506
  Multiple myeloma in the United States and India: An international, collaborative study comparing patient characteristics and treatment patterns.

  Guilherme Lopes, Gavin Miyasato, Meenal Sinha, Mohit Misra et al.
• 7567
  Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

  Okan Cetin, Gizem Teker, Raphael Elie Szalat
• 7550
  The future mortality trends in multiple myeloma (SEER analysis 2000–2030).

  Muhammad Talha Shaukat, Wania Ur Rehman, Hamlet Gasoyan, Yasar Shad et al.
• E24062
  Association between palliative care consultation and end-of-life care intensity in multiple myeloma.

  Muhammad Haseeb Khan, Rabbia Irfan, Nimra Niaz, Shamayel Safdar et al.
• E19500
  Artificial intelligence and machine learning in relapsed/refractory multiple myeloma: A systematic review.

  Kesar Prajapati, Kumar Anmol, Rahul Pottabathini, Sheilabi Seeburun et al.
• 7528
  Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM).

  Tanya Marya Wildes, Vera J. Suman, Jens Hillengass, Joseph Tario et al.
• E19578
  Ocular toxicity of belantamab mafodotin-based combination regimens in multiple myeloma: A systematic review of phase I-III clinical trials.

  Ahsun Rizwan Siddiqi, Tehrim Khan, Amna Zaheer, Shajadi Patan
• E23213
  The gap: Recognizing the inequities in oncology research and clinical practice guidelines—An analysis of clinical guidelines in multiple myeloma.

  Samuel Ranger, Maya Nicole Birhiray, Ruemu Ejedafeta Birhiray, Abbey Suess
• 7535
  Age-stratified late outcomes following bispecific antibody therapy in multiple myeloma: A real-world 6-month landmark analysis.

  Madhu Bhargavi Chandra, Fayaz Aijaz Ahmed Khan, Zuhair Alam
• E19539
  Time from diagnosis to treatment in multiple myeloma: A systematic review and meta-analysis.

  Porag Jeet Das, Nehemias Antonio Guevara Rodriguez, Hector J. Garcia Pleitez, Angela Spencer et al.
• E19538
  Real-world validation of the 2025 IMWG high-risk criteria in multiple myeloma.

  Rishil Chopra, Karen Johns, Zoe Ryan, Bradley T. Loeffler et al.
• E19525
  Treatment decision-making after CAR-T and bispecific antibody therapy in relapsed/refractory multiple myeloma: Real-world perspectives from U.S. hematologist/oncologists.

  Sarah Hendry, Olivia Parry, Kimberly Peihsi Ku
• TPS7582
  A phase 1b/2 study of mirdametinib in combination with sirolimus for patients with RAS-mutated relapsed/refractory multiple myeloma.

  Roshani Patel, Michael Emanuel, Ryan Young, Elizabeth M. Hill
• E13511
  Geographic disparities in availability of advanced therapies for myeloma from rural-urban access limitations: A population-based registry analysis.

  Mridula Preetham Talari, Chelsie Mackanos, Ankita Aggarwal, Ajay Iyer et al.
• E19552
  Fatal infection–associated adverse events with B-cell maturation antigen–directed therapies in multiple myeloma: A FAERS pharmacovigilance study.

  Valerin Arno, Aqsa Zoey Sorathia, Canan Dilay Dirican, Rouba Isshak et al.
• E24007
  Cardiovascular outcomes after bispecific T-cell-engager therapy in multiple myeloma: A propensity-matched real-world study.

  Nikhil Kumar Kotla, Roopeessh Vempati, Maya Hajeh, Haidar Hajeh et al.
• E19523
  CXCR4/CXCL12 antagonism to disrupt microenvironment-mediated resistance for autologous transplant conditioning in multiple myeloma: A systematic review and mechanistic synthesis.

  Jason A. Starr, Suzanne Rose, Christopher J. Del Prete, Joshua Dower
• E19577
  Trends and in-hospital outcomes of multiple myeloma in autoimmune rheumatic disease hospitalizations: A National Inpatient Sample analysis, 2016–2022.

  Naina Kumari, Barkha Kumari, Srijani Thannir, Ameerdad Khan et al.
• E19560
  Defining outcomes and risk of second primary malignancy (SPM) in patients with multiple myeloma (MM) in a large, integrated health system.

  Andrew Lynch, Shiyun Zhu, Faisal Cheema, Kevin Su et al.
• E19505
  Comparative incidence of infections and cytopenias in BCMA- vs GPRC5D-targeting bispecific antibodies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions.

  Sheilabi Seeburun, Marco Quirós, Mariano Gallo Ruelas
• E19509
  Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.

  Madhu Bhargavi Chandra, Fayaz Aijaz Ahmed Khan, Renu Bhargavi Boyapati, Zuhair Alam
• 11038
  Cost-effectiveness analysis of teclistamab plus daratumumab in relapsed or refractory multiple myeloma.

  Wing Fai Li, Junmin Song, Xiaoyi Zhang, Simo Du et al.
• E19518
  Machine learning–based identification of patients at risk for early infectious complications after CAR-T in multiple myeloma.

  Anushri Soni, Kimberly H. Seymour, Santiago Beltran, Emma Cordover et al.
• E19543
  Association of vitamin D deficiency with risk in multiple myeloma: A real-world cohort analysis.

  Khaled M. El-Husseiny, Alaa Mahmoud, Adnan Humam Hajjar, Himil Mahadevia et al.
• E23253
  Burden of disease management among patients with multiple myeloma and their care partners.

  Shiyin Jiao, Charlene Tugwete, Hilary Wilson, Christian Atkinson et al.
• E19519
  Comparative real-world outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma: A TriNetX observational study.

  Aneeq Mahmood Khan, Rubia Ali, Anitha Sangem, Zainab Rahim et al.
• E19527
  Impact of baseline severe cytopenia on post–BCMA CAR T-cell therapy outcomes in multiple myeloma: A propensity-matched multicenter study.

  Jesus Alberto Gomez, Divya Samat, Manas Pustake, Mohammad Arfat Ganiyani et al.
• E23047
  Divergence between regulatory approvals and guideline recommendations in multiple myeloma: Helping solve physician’s dilemmas with a real-time updated evidence library.

  Douglas B. Flora, Mihaela Musat, Anna Forsythe, Jessicca Martin Rege et al.
• E19108
  National burden and outcomes of CAR-T therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A retrospective analysis of the Nationwide Inpatient Sample.

  Varun Chowdhry, Sreeram Pannala, Praneeth Keesari, Ghaith Rababah et al.
• 7541
  CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.

  Jayasree Krishnan, Adithya Nagendran, Ian Lund, Anuja Vidyadhar Abhyankar et al.
• E19559
  Time to treatment initiation and clinical, toxicity, and supportive care outcomes in multiple myeloma: A real-world Epic Cosmos analysis.

  Varshini Srinivasan, Vasu Bansal, Mayank Goyal, Souvik Saha et al.
• E19562
  Long-term survival, disparities, and future burden of multiple myeloma: A population-based analysis.

  Sameer Krishna Prasad Garlapati, Madho Mal, Nayanika Chowdary Tummala, Rithish Nimmagadda et al.
• 7552
  Impact of human immunodeficiency virus on in-hospital outcomes among patients hospitalized with multiple myeloma: A National Inpatient Sample study, 2016–2022.

  Sophio Kakabadze, Max Jesus Bustillo Orozco, Mohammed Haroun, Darilis Patricia Palacio Bonill
• E19558
  Outcomes of de novo del(17p) in multiple myeloma.

  Sakthi Kumar, Nisha Joseph, Nishi Shah, Manali Rupji et al.
• E19557
  Impact of disseminated intravascular coagulation on in-hospital outcomes in patients with multiple myeloma: A nationwide analysis.

  Dua Azim, Jawad Ahmed, Abdul Ghani Iqbal, Farheen Malik et al.
• 7519
  Early detection of multiple myeloma and MGUS progression risk using artificial intelligence and routine laboratory data.

  Ciro Roberto Rinaldi, Syed Muhammad Ali Shah, Khaled Abdalgader Mohamed Omar Balawafi, Karim Tout et al.
• E19570
  Efficacy of venetoclax-based therapy in t(11;14)–positive relapsed/refractory multiple myeloma: A systematic review and meta-analysis.

  Vasu Malhotra, Shreya Ghanshyam Patel, Marialaina Carter, Sravani Bhavanam et al.
• E19547
  Early therapeutic intervention versus observation in high-risk smoldering multiple myeloma: A systematic review and meta-analysis.

  Swapnil Surpur, Aiman Waheed, Tushar Abhinav, Sameer Bhimani et al.
• E19531
  Insights through the renal lens: Clinical outcomes of newly diagnosed multiple myeloma patients with and without renal impairment in a resource-limited setting.

  Anoud Khan, Saqib Raza Khan, Munira Moosajee, Daania Shoaib et al.
• E19563
  LEN-EOS study: Lenalidomide-associated eosinophilia as a marker of response to induction therapy in multiple myeloma.

  Abhijith P B, Prasanth V. Parameswaran, Sreedharan P S, Arunmohan P V et al.
• E19537
  Differential clinical and economic signatures of CAR T-cell therapy in multiple myeloma across demographic and payer strata: A national analysis.

  Karnav Modi, Himil Mahadevia, Yajur Arya, Arshi Syal et al.
• 7517
  Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

  Jennifer H. Cooperrider, Andrew Daniel Kin, Jeffrey A. Zonder, Anna Ewa Pula et al.
• 7523
  Identifying high-risk cytogenetic subgroups in multiple myeloma using large language artificial intelligence models.

  John Culnan, Grace M. Ferri, Jennifer La, Clark DuMontier et al.
• 7573
  Early intravenous immunoglobulin use in multiple myeloma patients treated with talquetamab: Effect on risk of infections and mortality.

  Joseph OBrien, Monica Nair, Nicholas Bitz, James Ignatz-Hoover et al.
• 1532
  Transportation insecurity and RBC transfusion burden in multiple myeloma and related plasma cell disorders in New Mexico: A CRIIS statewide analysis (2013-2019).

  Altamash Jawadi, Stephanie Rosenberg, Kevin Angel Silva Parra, Ala Ebaid et al.
• 2550
  Anitocabtagene autoleucel (anito-cel) clinical trial manufacturing experience in patients with relapsed/refractory (RR) or newly diagnosed (ND) multiple myeloma (MM).

  Krina K. Patel, Clare Spooner, Monique Giordana, Taryn Shuler et al.
• 7551
  Machine learning to identify racial and socioeconomic disparities in the onset and tumor distribution of second primary malignancies in multiple myeloma.

  Muhammad Talha Shaukat, Wania Ur Rehman, Hamlet Gasoyan, Yasar Shad et al.
• E19540
  Impact of diabetes mellitus on inpatient outcomes among hospitalized patients with multiple myeloma: A National Inpatient Sample analysis (2018–2020).

  Eliza Aisha, Ruqiat Masooma, Amna Zaheer, Rida Fatima et al.
• 7574
  Comparative safety and efficacy of DKRd versus DVRd regimens in multiple myeloma: A systematic review and meta-analysis.

  M. Bakri Hammami, Shahem Alhaj Ahmad, Arwa M. Ibrahim, Fadel Anis et al.
• 7545
  Racial disparities in utilization of bispecific T-cell engager therapy for relapsed/refractory multiple myeloma: A TriNetX study.

  Emmanuel Ekpenyong, Chidiebube Ugwu, Maryam Mohsin, Bhawana Chhetri et al.
• E19549
  Long term follow up of multiple myeloma patients achieving MRD negativity at 10 -6 .

  Sanjay Muttineni, Sasya Dronavalli, Clyde Bailey, Samer Al Hadidi et al.
• E19501
  Comparative analysis of depression, anxiety, suicidality, substance use, and palliative care use in pain-afflicted multiple myeloma patients across White, Black, and Hispanic populations.

  Kesha Pathak, Aishwarya Ramesh, Dhruvi Dipakkumar Pathak, Krupa Savani et al.
• E23221
  Operationalizing bispecific antibody therapy in community oncology: Capturing insights on clinician preparedness for using off-the-shelf immunotherapy in lymphoma and multiple myeloma.

  Carmine Deluca, Michael Beyer, Hans C. Lee, Jennifer Leigh Crombie et al.
• 7572
  Incretin-based therapies and all-cause mortality and progression to multiple myeloma in patients with MGUS and type 2 diabetes: A real-world cohort study.

  Yousef Ateiwi, Mohammmad Amer Al Tamimi, Leen Alkuttob, Ahmad Al-Alwan et al.
• E19526
  Association of immunoglobulin replacement with infection and mortality outcomes in multiple myeloma patients receiving bispecific antibodies: A TriNetX analysis.

  Ahmad Al-Riyalat, Nadeen Majed Khraisat, Hassan Alkhatatneh, Laith Sorour et al.
• 7568
  Comparative efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs standard of care in patients with relapsed/refractory multiple myeloma (RRMM).

  Joshua Ryan Richter, Pragya Shukla, Venediktos Kapetanakis, Molly Purser et al.
• E19544
  Projected trends in ischemic heart disease mortality among patients with multiple myeloma in the United States: A forecast analysis through 2035.

  Daisha Rathod, Himanshu Khangwal, Neha Pillai Vinod, Purvy Manhari Ravula et al.
• E19541
  Trends and disparities in mortality due to coexisting respiratory infections and multiple myeloma among middle-aged and older adults in the United States.

  Masab Ali, Muhammad Hassan, Humza Saeed, Muhammad Abdullah et al.
• E19580
  HealthTree survey as an identifier of venous thromboembolism risk mitigation targets in newly diagnosed multiple myeloma.

  Muhamed Baljevic, Jay R. Hydren, Jorge Arturo Hurtado Martínez, Gliceida Galarza Fortuna et al.
• 7511
  Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma.

  Joseph OBrien, Monica Nair, Brenda W. Cooper, James John Ignatz-Hoover et al.
• 11189
  Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.

  Jay R. Hydren, Jorge Arturo Hurtado Martínez, Jennifer M. Ahlstrom, Douglas W. Sborov et al.
• E19521
  Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.

  Noffar Bar, Jungeun Yu, Jennifer Kelly, Rebecca Turk MacLeod et al.
• E22592
  Temporal and demographic trends in mortality from multiple myeloma with coexisting mental and behavioral disorders in U.S. adults, 1999–2023.

  Irza Shaikh, Sarim Hassan Shahab, Syeda Malika Naqvi, Minahil Zahid et al.
• E19554
  Self-reported ethnicity and outcomes of newly diagnosed multiple myeloma (NDMM) in the anti-CD38 monoclonal antibody era: A retrospective cohort study.

  Michael Sang Hughes, Andrew Doyle, Nadiya Yehxin Koth, Talia Shendelman et al.
• 7539
  Clinical outcomes following CAR T-cell therapy in relapsed or refractory multiple myeloma patients with baseline renal dysfunction: A TriNetX analysis.

  Preetinder Singh Manshahia, Juhi Ardeshna-Chovatiya, Ishan Jani, Aditya Sanjeevi et al.
• E19504
  Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).

  Nisha Joseph, Timothy Inocencio, Shannon Heitkamp, Thomas Delea et al.
• E24168
  Risk assessment models for venous thromboembolism in patients with multiple myeloma: A systematic review and meta-analysis.

  Pedro Luiz Lage Bodour Danielian, Alec Seidman Sorsby, Julia Kirsh, Amalia Stavropoulos et al.
• 7559
  SATMM: A systems genetic network analysis–based risk stratification tool validated across the disease trajectory of relapsed/refractory multiple myeloma.

  Carl Murie, Praneeth Reddy Sudalagunta, Serdar Turkarslan, Danny DeAvila et al.
• E19536
  Impact of chronic kidney disease on toxicity patterns and economic burden in CAR T-cell therapy for multiple myeloma: A national analysis.

  Himil Mahadevia, Karnav Modi, Yajur Arya, Arshi Syal et al.
• 7576
  Trends in frontline treatment patterns for multiple myeloma among US veterans, 1999–2025.

  Byron Seiya Sigel, Lawrence W. Liu, Cynthia Dong, Han Zhao et al.
• 7557
  Circulating tumor DNA NRAS and TP53 mutations to identify ultra-high-risk primary refractory myeloma patients.

  Sridurga Mithraprabhu, Thalia Perez-Suarez, Sueh-li Lim, Daniel Wong et al.
• E19530
  Mortality trend from multiple myeloma with hypertensive diseases as a contributing cause in the United States, 1999–2024: A CDC WONDER analysis across age, sex, and geographic variables.

  Siddhanta K.C., Maheen Rizwan, Mariam Mustafa, Zain Ali et al.
• E19574
  Matching-adjusted indirect comparison (MAIC) for belantamab mafodotin (belamaf) with pomalidomide and dexamethasone (BPd) vs daratumumab with pomalidomide and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM).

  Joshua Ryan Richter, Meral Beksaç, Alessandro Corso, Katerina Papadimitropoulou et al.
• 7548
  Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: A propensity score–matched analysis from a global federated health research network.

  Arshi Syal, Yajur Arya, Himil Mahadevia, Colton Jones et al.
• E19524
  Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.

  Amna Bint I Munir, Sapna Kumari, Haritha Gandicheruvu, Juhi Ardeshna-Chovatiya et al.
• 7527
  Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma.

  Junmin Song, Wing Fai Li, Yue Li, Toru Yoshino et al.
• E19548
  Epidemiological trends and burden of multiple myeloma mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.

  Md. Imran Hossain, Ibrahim Khalil, Anika Chowdhury, Sunjida Amin Promi et al.
• E19571
  Two decades of landscape change in the treatment of multiple myeloma.

  Meng Shu, Jingyu Xu, Hsingwen Chung, Yuntong Liu et al.
• E19546
  Multiple myeloma incidence, prevalence, and mortality burden in the United States: Retrospective epidemiological trends and burden (1990–2023) with machine learning-based projections to 2050.

  Md Abu Sayed, Ibrahim Khalil, Anika Chowdhury, Sunjida Amin Promi et al.
• E19532
  Age-centric insights: A single-center analysis of clinical presentation, treatment approaches, and outcomes in multiple myeloma patients across different age groups.

  Aryan Tareen, Saqib Raza Khan, Munira Moosajee, Sehrish Sarwar Baloch et al.
• E19553
  Trends in infection-related mortality among older adults with multiple myeloma in the United States over the last two decades.

  Ahad Moulvi, Ifrah Salim, Hamza Ehtesham, Faiz Anwer et al.
• TPS7579
  MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM).

  Binod Dhakal, Karthik Ramasamy, Amro Ali, Leah Leahy et al.
• E19516
  Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.

  Trilok Shrivastava, Sanjay Muttineni, Sasya Dronavalli, Hira Imad Cheema et al.
• 7509
  Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

  P. Joy Ho, Andrew Spencer, Sueh-li Lim, Stephanie Talam et al.
• 7529
  Association between survival outcomes in patients with multiple myeloma and treatment facility volume.

  Carl Ola Landgren, Gil Hevroni, Abhishek Pandey, Benjamin Diamond et al.
• 7544
  Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.

  Eli Zolotov, Behzad Amoozgar, Vanisha Patel, Reema Mody et al.
• 11055
  Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies.

  Hamlet Gasoyan, Shahzad Raza, Michael B. Rothberg, Jeffrey D. Kovach et al.
• 12051
  Early outpatient palliative care for patients with multiple myeloma: A randomized pilot study.

  Breffni Hannon, Samantha Lo, Criselda Isabel Cenizal, Timo Carpen et al.
• 7538
  How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.

  Eva Duvalyan, Jihong Song, Samantha Shenoy, Chiung-Yu Huang et al.
• 7512
  Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study.

  Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Nikolaos Kanellias et al.
• 7554
  Copy number aberration profiling using shallow whole-genome sequencing-based LeukoPrint in multiple myeloma.

  Li Gao, Liping Su, Fengyan Jin, Zhongxing Jiang et al.
• 7560
  A common gene expression signature across multiple myeloma disease stages to identify high-risk of disease progression.

  Claudio Cerchione, Nour Alassi, Sarah Tassinari, Delia Cangini et al.
• 7570
  Minimal residual disease dynamics in newly diagnosed multiple myeloma and impact on progression-free survival: A cohort study.

  Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis Kostopoulos, Charalampos Filippatos et al.
• E19556
  Second primary malignancies after CAR-T versus SCT in multiple myeloma.

  Shahzad Raza, Kirti Arora, Stuti Shah, Rishi Chowdhary et al.
• 7546
  cfDNA WGS vs plasma proteomics for minimally invasive MRD assessment in multiple myeloma.

  Dor Abelman, Aimee Wong, Jenna Eagles, Saumil Shah et al.
• 7530
  Gaps in access to chimeric antigen receptor T-cell (CAR-T) therapy post leukapheresis: Waiting time and post-leukapheresis treatment patterns in relapsed/refractory multiple myeloma (RRMM)—Real-world evidence from U.S. claims.

  Sikander Ailawadhi, Natalie Boytsov, Jasjit Multani, Zifan Zhou et al.
• 7564
  Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

  Marcelo Capra, Gurdeep Parmar, Fernanda Seguro, Vania Hungria et al.
• 1513
  Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma.

  Areej El-Jawahri, Cheri Marmarosh, Suzanne Hollman, Upeka Samarakoon et al.
• 7525
  An integrated population pharmacokinetic/pharmacodynamic (popPK/PD) model to select the linvoseltamab (LINVO) dosing regimen in patients with high-risk smoldering multiple myeloma (HR-SMM).

  Brett Matzuka, Anasuya Hazra, Sheila Masinde, Lutz Harnisch et al.
• E19511
  Infection burden with BCMA versus GPRC5D-targeted bispecific antibodies in multiple myeloma: A systematic review and meta-analysis.

  Hector J. Garcia Pleitez, Nehemias Guevara, Porag Jeet Das, Mary A. Elhawi et al.
• TPS7580
  A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma.

  Hans C. Lee, Luciano J. Costa, Binod Dhakal, Christopher J. Ferreri et al.
• E19507
  Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.

  Jindriska Lindsay, Werner Freier, John Jones, Supratik Basu et al.
• 7534
  Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.

  Stefan Longobardi, Shoon Lei Oo, Asis Shrestha, Anup Kumar Trikannad et al.
• 7549
  Duffy-null status and cytopenias following BCMA-directed CAR T therapy in multiple myeloma.

  Christen Marie Dillard, Erneisha Brown, Oren Pasvolsky, Mahmoud R. Gaballa et al.
• 7500
  Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

  Cyrille Touzeau, Fredrik Schjesvold, Claudio Cerchione, Xavier P. Leleu et al.
• E19513
  Can a simple pre-mobilization complete blood count predict stem cell yield? Low-cost predictors of CD34⁺ mobilization in multiple myeloma.

  Ancy Peter, Prasanth Parameswaran, Narayanankutty Edavalath Warrier, Raghuveer Prabhu et al.
• E19564
  Association between clonal plasma cell S-phase after autologous stem cell transplantation and survival outcomes in multiple myeloma.

  Tamer Hellou, Daniel G. Packard, Maximilian J. Steinhardt, Shaji Kumar et al.
• 7561
  Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.

  Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt et al.
• E19576
  Clinical profile, treatment patterns, and survival outcomes of multiple myeloma patients in the Middle East: Real-world data from Bahrain.

  Shruti Prem Sudha, Amal Almutawa, Nabil Abdelfattah, Taif Najeebi et al.
• 7540
  Expansion of a highly activated (HLA-DR+/CD38+) CAR T cell population after mezigdomide exposure post–idecabtagene vicleucel infusion in relapsed multiple myeloma.

  Lawrence W. Liu, Scott Ryan Goldsmith, Preeti Sharma, Ottavio Napolitano et al.
• E19566
  MACROD2 and CDKN2A in multiple myeloma: Insights to germline susceptibility and cytogenetic risk from long-read Nanopore sequencing.

  Panteha Behboodi, James Di Palma Grisi, Andy Madrid, Martha Salas et al.
• 7516
  Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.

  Albert Oriol Rocafiguera, Marek Hus, Raimundo Gazitua, Aijun Liao et al.
• 7514
  Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.

  Prashant Kapoor, Shaji Kumar, Eli Muchtar, Wilson I. Gonsalves et al.
• 7536
  Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.

  Roberto Mina, Niels W.C.J. van de Donk, Cyrille Touzeau, Yaël C. Cohen et al.
• 7508
  Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.

  Saurabh Chhabra, Emma Searle, Rakesh Popat, Hila Magen et al.
• E19503
  Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.

  Meletios A. Dimopoulos, Jorge Monge Urrea, Efstathios Kastritis, Xavier P. Leleu et al.
• 7562
  ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

  Andrew J. Yee, Clifton Craig Mo, Andrew Robert Branagan, Monique A. Hartley-Brown et al.
• LBA7506
  Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.

  Paul G. Richardson, Fredrik Schjesvold, Chengcheng Fu, Monique A. Hartley-Brown et al.
• 7503
  DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).

  Saad Z. Usmani, Michał Mielnik, Aránzazu Alonso, Al-Ola A. Abdallah et al.
• 7532
  Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).

  Maen A. Hussein, Chai Kim, Yong Chen, Ariel Grajales-Cruz et al.
• TPS7577
  QUINTESSENTIAL-2: A phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide.

  Eyal Lebel, Ahmed Abdulgawad, Stefania Bramanti, P. Joy Ho et al.
• 7526
  Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.

  Hans C. Lee, Naresh Bumma, Joshua Ryan Richter, Jeffrey A. Zonder et al.
• 7504
  Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.

  Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, Angelo Belotti et al.
• 7565
  Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.

  Meletios A. Dimopoulos, Meral Beksaç, Sosana Delimpasi, Vladimir I. Vorobyev et al.
• 7515
  Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.

  Suzanne Trudel, Güldane Cengiz Seval, Sosana Delimpasi, Vladimir I. Vorobyev et al.
• 7513
  Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.

  Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar Jacques J. Bahlis et al.
• 7520
  Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.

  Arjun Raj Rajanna, Jorge Arturo Hurtado Martínez, David Glen Coffey, Dickran Garo Kazandjian et al.
• 7569
  Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

  Christopher P. Venner, Sonja Zweegman, Shaji Kumar, Thierry Facon et al.
• 7566
  PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

  Güldane Cengiz Seval, Sosana Delimpasi, Vladimir I. Vorobyev, Hang Quach et al.
• 7507
  MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

  Roberto Mina, Cyrille Touzeau, Vania Hungria, Carl Ola Landgren et al.
• 7510
  Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

  Peter Forsberg, David Andorsky, Robert M. Rifkin, Christopher A. Yasenchak et al.